UNITED THERAPEUTICS Corp
UTHRAPI behind this page
UTHR FY 2025 request
Playground key active
/api/financials?ticker=UTHR&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 3,182.7 | 2,877.4 | +10.6% |
Show Product Lines breakouts |
|||
| Adcirca | 30 | 23.8 | +26.1% |
| Adcirca · Eli Lilly & Co. | 1,000,000 | — | — |
| Adcirca · US | 30 | 23.8 | +26.1% |
| Nebulized Tyvaso | 585.7 | 586.8 | -0.2% |
| Nebulized Tyvaso · Non Us | 53.8 | 41.3 | +30.3% |
| Nebulized Tyvaso · US | 531.9 | 545.5 | -2.5% |
| Orenitram | 496.9 | 434.3 | +14.4% |
| Orenitram · US | 496.9 | 434.3 | +14.4% |
| Product And Service Other | 24 | 22.1 | +8.6% |
| Product And Service Other · Non Us | 1.2 | 3 | -60.0% |
| Product And Service Other · US | 22.8 | 19.1 | +19.4% |
| Remodulin | 526.8 | 538.1 | -2.1% |
| Remodulin · Non Us | 77.9 | 73.9 | +5.4% |
| Remodulin · US | 448.9 | 464.2 | -3.3% |
| Tyvaso [Member] | 1,878.2 | 1,620.4 | +15.9% |
| Tyvaso [Member] · Non Us | 54.5 | 41.7 | +30.7% |
| Tyvaso [Member] · US | 1,823.7 | 1,578.7 | +15.5% |
| Tyvaso DPI | 1,292.5 | 1,033.6 | +25.0% |
| Tyvaso DPI · Non Us | 0.7 | 0.4 | +75.0% |
| Tyvaso DPI · US | 1,291.8 | 1,033.2 | +25.0% |
| Unituxin | 226.8 | 238.7 | -5.0% |
| Unituxin · Non Us | 12.1 | 19.1 | -36.6% |
| Unituxin · US | 214.7 | 219.6 | -2.2% |
Show Geography breakouts |
|||
| Non Us | 145.7 | 137.7 | +5.8% |
| US | 3,037 | 2,739.7 | +10.9% |
| Cost of Revenue | 384.4 | 309.7 | +24.1% |
Show Product Lines breakouts |
|||
| Adcirca | 13.1 | 10.1 | +29.7% |
| Nebulized Tyvaso | 27.2 | 34.1 | -20.2% |
| Orenitram | 28.7 | 28.4 | +1.1% |
| Product And Service Other | 38 | 26.9 | +41.3% |
| Remodulin | 49.3 | 47.4 | +4.0% |
| Tyvaso DPI | 210.6 | 148.4 | +41.9% |
| Unituxin | 17.5 | 14.4 | +21.5% |
| Research & Development | 550 | 481 | +14.3% |
| Selling, General & Administrative | 755.8 | 709.7 | +6.5% |
| Total Costs & Expenses | 1,690.2 | 1,500.4 | +12.6% |
| Operating Income | 1,492.5 | 1,377 | +8.4% |
| Interest Income | 192 | 199.1 | -3.6% |
| Interest Expense | -19.5 | -42.9 | +54.5% |
| Other Non-Operating Income (Expense) | 48.9 | 5.8 | +743.1% |
| Non-Operating Income (Expense) | 221.4 | 162 | +36.7% |
| Income Before Taxes | 1,713.9 | 1,539 | +11.4% |
| Income Tax Expense (Benefit) | -379.2 | -343.9 | -10.3% |
| Net Income | 1,334.7 | 1,195.1 | +11.7% |
Show Equity Components breakouts |
|||
| Retained Earnings | 1,334.7 | 1,195.1 | +11.7% |
| EPS (Basic) | 30.13 | 26.44 | +14.0% |
| EPS (Diluted) | 27.86 | 24.64 | +13.1% |
| Wtd Avg Shares (Basic) | 44.3 | 45.2 | -2.0% |
| Wtd Avg Shares (Diluted) | 47.9 | 48.5 | -1.2% |
| Gross Profit | 2,798.3 | 2,567.7 | +9.0% |
Show Product Lines breakouts |
|||
| Adcirca | 16.9 | 13.7 | +23.4% |
| Nebulized Tyvaso | 558.5 | 552.7 | +1.0% |
| Orenitram | 468.2 | 405.9 | +15.3% |
| Product And Service Other | -14 | -4.8 | -191.7% |
| Remodulin | 477.5 | 490.7 | -2.7% |
| Tyvaso DPI | 1,081.9 | 885.2 | +22.2% |
| Unituxin | 209.3 | 224.3 | -6.7% |
| Comprehensive Income | 1,339 | 1,204.5 | +11.2% |
| Other Comprehensive Income | 4.3 | 9.4 | -54.3% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -5.4 | -4.9 | -10.2% |
| Accumulated Net Unrealized Investment Gain Loss | 9.7 | 11.9 | -18.5% |
| Accumulated Other Comprehensive Income | 4.3 | 9.4 | -54.3% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,557.1 | 1,697.2 | -8.3% |
| Marketable Securities (Current) | 1,363.2 | 1,569.8 | -13.2% |
| Accounts Receivable | 350.2 | 279.3 | +25.4% |
| Inventory | 183.1 | 157.9 | +16.0% |
| Other Assets Current | 248.9 | 169.7 | +46.7% |
| Total Current Assets | 3,702.5 | 3,873.9 | -4.4% |
| Non-Current Assets | |||
| Marketable Securities (Non-Current) | 1,776.7 | 1,475.3 | +20.4% |
| Property, Plant & Equipment | 1,729.7 | 1,222.4 | +41.5% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 55.7 | — | — |
Show Property Plant And Equipment By Type breakouts |
|||
| Leasehold Improvements | 28.8 | — | — |
| Deferred Tax Assets | 357.7 | 458.4 | -22.0% |
| Other Non-Current Assets | 196.9 | 222.1 | -11.3% |
| Total Assets | 7,880 | 7,364 | +7.0% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Not Primary Beneficiary | 21.2 | 13.8 | +53.6% |
| Operating Lease Right-of-Use Assets (Q) | — | — | — |
Show Property Plant And Equipment By Type breakouts |
|||
| Building | 8.8 | — | — |
| Goodwill | 32.3 | 32.3 | 0.0% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Other Intangible Assets | 5.7 | 1.1 | +418.2% |
| Other Assets | |||
| Intangible Assets Net Including Goodwill | 116.5 | 111.9 | +4.1% |
| Current Liabilities | |||
| Accounts Payable And Accrued Liabilities Current | 488 | 344.5 | +41.7% |
| Other Liabilities Current | 72.6 | 93.6 | -22.4% |
| Total Current Liabilities | 560.6 | 738.1 | -24.0% |
| Accounts Payable | 7.1 | 6 | +18.3% |
| Accrued Liabilities | 480.9 | 338.5 | +42.1% |
| Non-Current Liabilities | |||
| Other Non-Current Liabilities | 223.2 | 181.9 | +22.7% |
| Total Liabilities | 783.8 | 920 | -14.8% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Not Primary Beneficiary | 3.2 | 5.6 | -42.9% |
| Stockholders' Equity | |||
| Common Stock | 0.8 | 0.8 | 0.0% |
| Additional Paid In Capital Common Stock | 2,798 | 2,698.9 | +3.7% |
| Accumulated Other Comprehensive Income | 0.9 | -3.4 | +126.5% |
| Treasury Stock Common Value | -4,260.4 | -3,474.5 | -22.6% |
| Retained Earnings | 8,556.9 | 7,222.2 | +18.5% |
| Total Stockholders' Equity | 7,096.2 | 6,444 | +10.1% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 5.6 | 11 | -49.1% |
| Accumulated Net Unrealized Investment Gain Loss | 10.8 | 1.1 | +881.8% |
| Accumulated Other Comprehensive Income | 0.9 | -3.4 | +126.5% |
| Accumulated Translation Adjustment | -15.5 | -15.5 | 0.0% |
| Additional Paid In Capital | 2,798 | 2,698.9 | +3.7% |
| Common Stock | 0.8 | 0.8 | 0.0% |
| Retained Earnings | 8,556.9 | 7,222.2 | +18.5% |
| Treasury Stock Common | -4,260.4 | -3,474.5 | -22.6% |
| Total Liabilities & Equity | 7,880 | 7,364 | +7.0% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 85.6 | 72.5 | +18.1% |
| Stock-Based Compensation | 147.7 | 144 | +2.6% |
| Impairment Of Long Lived Assets Held For Use | 21.7 | — | — |
| Deferred Income Taxes | 97.7 | -64.1 | +252.4% |
| Other Non-Cash Items | -19.7 | -24.3 | +18.9% |
| Change in Accounts Receivable | -70.9 | -0.4 | -17625.0% |
| Change in Inventory | -52.6 | -46.9 | -12.2% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 97.9 | 42.7 | +129.3% |
| Increase Decrease In Other Operating Capital Net | -80.9 | 8.5 | -1051.8% |
| Net Cash from Operations | 1,561.2 | 1,327.1 | +17.6% |
| Investing Activities | |||
| Capital Expenditures | -520.5 | -246.5 | -111.2% |
| Payments To Acquire Intangible Assets | -5.5 | — | — |
| Advance Payment Related To Property Plant And Equipment | -10.4 | -28.5 | +63.5% |
| Purchases of Investments | -3,405.4 | -1,646.1 | -106.9% |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 1,583.9 | 1,537 | +3.1% |
| Proceeds From Sale Of Available For Sale Securities Debt | 1,861.6 | 831.8 | +123.8% |
| Payments To Acquire Equity Securities Without Readily Determinable Fair Value | -55 | -30.5 | -80.3% |
| Net Cash from Investing | -551.3 | 417.2 | -232.1% |
| Financing Activities | |||
| Share Repurchases | -1,000 | -1,000 | 0.0% |
| Proceeds From Lines Of Credit | 200 | — | — |
| Repayments Of Lines Of Credit | -500 | -400 | -25.0% |
| Excise Tax Paid On Net Share Repurchase Financing Activities | -5 | — | — |
| Debt Issuance Costs | -11.5 | -2.7 | -325.9% |
| Proceeds From Stock Options Exercised | 173.9 | 152.5 | +14.0% |
Show Award Type breakouts |
|||
| Employee Stock Option | 173.9 | 152.5 | +14.0% |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans | 9.2 | 7.6 | +21.1% |
| Tax Withholding for Share Compensation | -16.6 | -12.2 | -36.1% |
| Net Cash from Financing | -1,150 | -1,254.8 | +8.4% |
| Supplemental | |||
| Interest Paid | 13.5 | 40.2 | -66.4% |
| Income Taxes Paid | 313.3 | 400.6 | -21.8% |
| Unpaid Capital Expenditures | 116.3 | 22.2 | +423.9% |
| Noncash Excise Tax On Net Share Repurchases | 1.8 | 5 | -64.0% |
| Other Cash Flow | |||
| Net Change in Cash | -140.1 | 489.5 | -128.6% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,557.1 | 1,697.2 | -8.3% |
Values in millions USD. Source: SEC EDGAR 10-K filing.